发现以p53-MDM2作为抗癌剂的混合化合物
Mai A Mansour1, Ghaneya S Hassan1,2, Maiy Y Jaballah3
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt.
Archiv der Pharmazie
|September 3, 2025
概括
研究人员开发了新型的pyrazoline化合物来抑制p53-MDM2相互作用,恢复p53的瘤抑制功能,用于潜在的抗癌疗法. 化合物6d显示出显著的抗增殖活性和对癌细胞的选择性.
科学领域:
- 医学化学
- 分子生物学
- 癌症学
背景情况:
- 这种p53-MDM2相互作用抑制瘤抑制蛋白p53, 代表抗癌药物开发的目标.
- 恢复p53功能是新型癌症治疗的有希望的策略.
研究的目的:
- 设计,合成和评估新型pyrazoline衍生化合物作为p53-MDM2相互作用的抑制剂.
- 探索从现有抑制剂 (Nutlin-2) 跳跃到酸盐核心的支架.
主要方法:
- 使用基架跳跃和分子对接来设计潜在的p53-MDM2抑制剂.
- 使用NCI60细胞系组进行了抗增殖活性评估.
- 生物化学测定 (ELISA,西部) 和细胞毒性研究评估了化合物的疗效和选择性.
- 通过X射线结晶学证实了化合物的立体化学成分.
主要成果:
- 合成了新的pyrazoline化合物,其中6c,6d和9d化合物具有显著的抗增殖活性.
- 化合物6d对NCI60细胞系的平均GI50为8. 39μM,对MDM2的生物化学IC50为13. 8μM.
- 化合物6d对癌细胞的选择性超过正常细胞,并调节了p53和MDM2的表达.
- 通过分子对接和X射线结晶学证实了结合方向.
结论:
- 皮拉衍生化合物是p53-MDM2相互作用的有效抑制剂.
- 通过恢复p53功能,化合物6d是开发向抗癌药物的有希望的候选物.
- 这项研究突显了pyrazoline支架在抗癌药物发现中的潜力.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


